Nuevolution AB (NUE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nuevolution AB (NUE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9386
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nuevolution AB (Nuevolution) is a biopharmaceutical company focused on developing drug treatments for cancer and chronic inflammatory diseases. The company’s pipeline products include RORyt inhibitor, BRD (BD1), cytokine X, RORyt agonist, and GRP78. Its products are used for various indications such as dermatology, psoriatic arthritis, inflammation, immune-oncology, and oncology. Nuevolution also develops Chemetics, a patent protected drug discovery platform that enables the discovery of novel small molecule tablet based drug candidates and provides access to screening of billions of molecules and optimization of drug properties in the process of identifying the drug candidate. The company partners with other pharma and biotech companies for its drug discovery and development. Nuevolution is headquartered in Copenhagen, Denmark.

Nuevolution AB (NUE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nuevolution AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nuevolution Raises US$13.7 Million Venture Financing Round 11
Partnerships 12
Nuevolution Enters into Co-Development Agreement with Almirall 12
Nuevolution Enters into Research Agreement with Amgen 13
Nuevolution Enters into Discovery Agreement with Janssen Biotech 14
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 15
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 17
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 18
Licensing Agreements 19
Amgen Exercises Option for Licensing Agreement with Nuevolution 19
Janssen Biotech Enters into Licensing Agreement with Nuevolution 20
Nuevolution Enters Into Licensing Agreement With Novartis 21
Equity Offering 22
Nuevolution Raises USD290 Million in IPO of Shares 22
Nuevolution AB – Key Competitors 23
Nuevolution AB – Key Employees 24
Nuevolution AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
May 08, 2018: Nuevolution announces its results for the first quarter of 2018 and provides update on partnership discussions 26
Feb 08, 2018: Nuevolution announces its year-end report for 2017 and report for the three-month period ended 31 December 2017 27
Sep 06, 2017: Nuevolution announces its results for the fourth quarter and full year 2016/17 28
May 17, 2017: Nuevolution announces its results for the third quarter 2016/17 29
Corporate Communications 30
Apr 24, 2018: Nuevolution’s Board of Directors to Be Reduced From Six to Five Members 30
Jan 23, 2018: Nuevolution appoint Dr. Paul Scigalla as Chief Medical Officer on consultancy basis 31
Oct 30, 2017: Fredrik Arp is Proposed as Board Member in Nuevolution 32
Legal and Regulatory 33
Dec 08, 2017: The Danish Eastern High Court revokes the Maritime and Commercial High Court’s decision of 22 February 2016 in favour of Nuevolution’s request 33
Product News 34
08/22/2018: Nuevolution discloses the identity of its Cytokine X program being interleukin IL-17A and initiates promotion of its small molecule IL-17A inhibitor program targeting inflammatory diseases 34
May 17, 2018: Nuevolution announces the publication of a second scientific article from the collaboration with Nobel Laureate Dr. Robert J. Lefkowitz 35
Feb 14, 2017: Nuevolution Technology Progress: Nuevolution Scales its Compound Collection to 40 Trillion Using its Chemetics Drug Discovery Platform 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Nuevolution AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Deals By Therapy Area, 2012 to YTD 2018 9
Nuevolution AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Raises US$13.7 Million Venture Financing Round 11
Nuevolution Enters into Co-Development Agreement with Almirall 12
Nuevolution Enters into Research Agreement with Amgen 13
Nuevolution Enters into Discovery Agreement with Janssen Biotech 14
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 15
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 17
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 18
Amgen Exercises Option for Licensing Agreement with Nuevolution 19
Janssen Biotech Enters into Licensing Agreement with Nuevolution 20
Nuevolution Enters Into Licensing Agreement With Novartis 21
Nuevolution Raises USD290 Million in IPO of Shares 22
Nuevolution AB, Key Competitors 23
Nuevolution AB, Key Employees 24
Nuevolution AB, Subsidiaries 25

List of Figures
Nuevolution AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nuevolution AB (NUE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • WNDM Medical Inc (WNDM):製薬・医療:M&Aディール及び事業提携情報
    Summary WNDM Medical Inc (WNDM Medical), formerly Wound Management Technologies Inc is a distributor of biotechnology products to hospitals, physicians, and clinics. The company offers its patented product CellerateRX in powder and gel forms, and hemaquell resorbable bone wax that controls bone blee …
  • Advicenne SA (ADVIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It p …
  • Eindec Corporation Ltd (42Z):企業の財務・戦略的SWOT分析
    Eindec Corporation Ltd (42Z) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • ADVA Optical Networking SE (ADV):企業の財務・戦略的SWOT分析
    ADVA Optical Networking SE (ADV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • NorthWestern Corp:企業の発電所・SWOT分析2018
    NorthWestern Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • BMG Resources Ltd (BMG):企業の財務・戦略的SWOT分析
    Summary BMG Resources Ltd (BMG), formerly known as Brazilian Metals Group Ltd, is a mineral exploration company that explores lithium brine in Chile. The company's portfolio includes exploration tenements located in the Republic of Cyprus. Its product portfolio include nickel, gold, copper, cobalt, …
  • Toyota Tsusho Corp (8015):電力:M&Aディール及び事業提携情報
    Summary Toyota Tsusho Corp (Toyota Tsusho) is a diversified general trading and project management company. The company trades steel, aluminum, machinery, electronics, energy, chemicals, and other consumer products. It also provides passenger cars, buses, motorcycles, trucks, used vehicles, electron …
  • OFG Bancorp (OFG):企業の財務・戦略的SWOT分析
    Summary OFG Bancorp (OFG) is a financial service provider that offers banking, treasury, and financial products and services. The company’s consumer banking and lending products comprise residential mortgages, consumer finance, auto loans, and credit cards. Its commercial banking products and servic …
  • Micromedic Technologies Ltd (MCTC):医療機器:M&Aディール及び事業提携情報
    Summary Micromedic Technologies Ltd (Micromedic) is a medical device company that develops and manufactures in vitro cancer diagnostic products and solutions. The company offers products such as histo-chemical platform, genetic assays for personalized medicine and molecular biomarker assays. It prov …
  • Insperity Inc (NSP)
    Insperity Inc (NSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Glorious Sun Enterprises Limited (393):企業の財務・戦略的SWOT分析
    Glorious Sun Enterprises Limited (393) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Carillion plc:戦略・SWOT・企業財務分析
    Carillion plc - Strategy, SWOT and Corporate Finance Report Summary Carillion plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • CWC Energy Services Corp (CWC):企業の財務・戦略的SWOT分析
    Summary CWC Energy Services Corp (CWC) formerly CWC Well Services Corp, is an oilfield servicing company that provides drilling rigs, service rigs, coil tubing and well testing services in the Western Canadian Sedimentary Basin. The company operates through two divisions such as contract drilling an …
  • Touchstone Group plc:企業の戦略的SWOT分析
    Touchstone Group plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Argos Therapeutics Inc (ARGS):製薬・医療:M&Aディール及び事業提携情報
    Summary Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherap …
  • Bio Blast Pharma Ltd (ORPN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bio Blast Pharma Ltd (Bioblast Pharma) is a clinical stage biotechnology company that discovers, delivers, and develops clinical therapies for patients with rare and ultra-rare genetic diseases. The company discovers and develops pipeline products using platforms such as cabaletta, a mutant …
  • Vp Plc (VP.):企業の財務・戦略的SWOT分析
    Summary Vp Plc (Vp) is a provider of equipment rental services. The company offers material handling equipment rental for housing, general construction and other industries; equipment for shoring and piling, pipe stoppers, pumps, temporary bridges and excavation support equipment for water, gas, civ …
  • Ansaldo Energia SpA:電力:M&Aディール及び事業提携情報
    Summary Ansaldo Energia SpA (Ansaldo Energia), a subsidiary of CDP Equity SpA, is a power generation company and a supplier of power plant equipment and related services. It provides power plant equipment such as gas turbines, steam turbines, turbo generators, and hydro-generators used in fossil fue …
  • Destination Maternity Corporation (DEST):企業の財務・戦略的SWOT分析
    Destination Maternity Corporation (DEST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • The Nippon Synthetic Chemical Industry Co Ltd:企業の戦略的SWOT分析
    The Nippon Synthetic Chemical Industry Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆